Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study.
We explored the effectiveness of liposomal polyvinyl-pyrrolidone (PVP)-iodine hydrogel for treating chronic inflammatory skin conditions, including acne. In our study, 30 participants with acne vulgaris received a 3% PVP-iodine hydrogel for up to four weeks.
By examining the Global Clinical Severity Score, we observed a notable improvement specific to acne, with a score change of 0.5, which was statistically significant. Alongside this, enhancements in pain levels and overall quality of life were also reported.
Importantly, the treatment was generally well tolerated, with only minor side effects such as burning or itching experienced by a small percentage of participants. Overall, these findings suggest that liposomal PVP-iodine hydrogel could be a promising option for managing acne and potentially other skin infections related to bacterial presence.
Read More
Most Useful Reviews
2
Increased cystic acne
248 people found this helpful
Powerful stuff—be cautious. A daily capsule raised my basal body temperature half a degree. It worked quickly, making me feel less hungry and reducing sugar cravings. However, I’ve noticed some cystic acne returning, so I might cut back to every other day. It's clearly powerful, but small doses of iodine can lead to hypothyroid symptoms. Take care and good luck!
Read More
7.5
Dosage matters
102 people found this helpful
Kelp may cause acne if taken in high doses. If you notice your skin breaking out, reduce your intake to every other day instead of daily. Kelp can address symptoms of an underactive thyroid, and I definitely recommend it, but be informed about dosing to avoid skin issues.
Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study.
We explored the effectiveness of liposomal polyvinyl-pyrrolidone (PVP)-iodine hydrogel for treating chronic inflammatory skin conditions, including acne. In our study, 30 participants with acne vulgaris received a 3% PVP-iodine hydrogel for up to four weeks.
By examining the Global Clinical Severity Score, we observed a notable improvement specific to acne, with a score change of 0.5, which was statistically significant. Alongside this, enhancements in pain levels and overall quality of life were also reported.
Importantly, the treatment was generally well tolerated, with only minor side effects such as burning or itching experienced by a small percentage of participants. Overall, these findings suggest that liposomal PVP-iodine hydrogel could be a promising option for managing acne and potentially other skin infections related to bacterial presence.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 2 Reviews
7.7
All Reviews
Positive Reviews
Negative Reviews
2
Increased cystic acne
248 people found this helpful
Powerful stuff—be cautious. A daily capsule raised my basal body temperature half a degree. It worked quickly, making me feel less hungry and reducing sugar cravings. However, I’ve noticed some cystic acne returning, so I might cut back to every other day. It's clearly powerful, but small doses of iodine can lead to hypothyroid symptoms. Take care and good luck!
Read More
7.5
Dosage matters
102 people found this helpful
Kelp may cause acne if taken in high doses. If you notice your skin breaking out, reduce your intake to every other day instead of daily. Kelp can address symptoms of an underactive thyroid, and I definitely recommend it, but be informed about dosing to avoid skin issues.
Read More
Frequently Asked Questions
No FAQs are available for this product and symptom.
References
Augustin M, Goepel L, Jacobi A, Bosse B, Mueller S, et al. Efficacy and tolerability of liposomal polyvinylpyrrolidone-iodine hydrogel for the localized treatment of chronic infective, inflammatory, dermatoses: an uncontrolled pilot study. Clin Cosmet Investig Dermatol. 2017;10:373. 10.2147/CCID.S141887